Endometrial carcinoma

Annual Review of Pathology

Volumn 2, Issue , 2007, Pages 57-85

  Di Cristofano, Antonio ^a   Ellenson, Lora Hedrick ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Endometrioid; Estrogen receptor; Molecular genetics; Mouse models; PTEN; Serous

Indexed keywords

GROWTH FACTOR;

CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; GROWTH REGULATION; HUMAN; MITOGENESIS; MOLECULAR GENETICS; MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

EID: 33947427878     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.2.010506.091905     Document Type: Review

References (146)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. 2006. Cancer statistics, 2006. CA Cancer J. Clin. 56:106-30
2. Bokhman JV. 1983. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15:10-17
3. Sherman ME, Sturgeon S, Brinton LA, Potischman N, Kurman RJ, et al. 1997. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod. Pathol. 10:963-68
4. Kurman RJ. 2002. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag
5. Kurman RJ, Kaminski PF, Norris HJ. 1985. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 56:403-12
6. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, et al. 2006. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106:812-19
7. Kendall BS, Ronnett BM, Isacson C, Cho KR, Hedrick L, et al. 1998. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am. J. Surg. Pathol. 22:1012-19
8. Bergeron C, Nogales FF, Masseroli M, Abeler V, Duvillard P, et al. 1999. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am. J. Surg. Pathol. 23:1102-8
9. Randall TC, Kurman RJ. 1997. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet. Gynecol. 90:434-40
10. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, et al. 2004. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann. Oncol. 15:1173-78
11. Nori D, Hilaris BS, Tome M, Lewis JLJ, Birnbaum S, Fuks Z. 1987. Combined surgery and radiation in endometrial carcinoma: an analysis of prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 13:489-97
12. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. 1982. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 6:93-108
13. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. 1995. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum. Pathol. 26:1260-67
14. Baergen RN, Warren CD, Isacson C, Ellenson LH. 2001. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int. J. Gynecol. Pathol. 20:214-19
15. Vaidya AP, Littell R, Krasner C, Duska LR. 2006. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int. J. Gynecol. Cancer 1(Suppl. 16):267-72
16. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, et al. 1997. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:356-62
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-47
18. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, et al. 1998. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer Res. 4:3005-10
19. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, et al. 1997. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57:3935-40
20. Simpkins SB, Peiffer-Schneider S, Mutch DG, Gersell D, Goodfellow PJ. 1998. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol. Oncol. 71:391-95
21. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. 1998. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 58:3254-58
22. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, et al. 1998. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 58:2500-3
23. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. 1997. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57:3660-63
24. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, et al. 1997. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 57:4187-90
25. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, et al. 1998. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 95:5246-50
26. Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273:13375-78
27. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, et al. 1998. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA 95:13513-18
28. Sakurada A, Hamada H, Fukushige S, Yokoyama T, Yoshinaga K, et al. 1999. Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer. Int. J. Oncol. 15:1069-74
29. 1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res. 61:4569-75
30. 1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum. Mol. Genet. 10:599-604
31. Nishimura Y, Watanabe J, Jobo T, Kato N, Fujisawa T, et al. 2004. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. Anticancer Res. 24:2185-91
32. Risinger JI, Hayes AK, Berchuck A, Barrett JC. 1997. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57:4736-38
33. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. 2001. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res. 61:4311-14
34. Chung JH, Eng C. 2005. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res. 65:8096-100
35. Oda K, Stokoe D, Taketani Y, McCormick F. 2005. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65:10669-73
36. Bilbao C, Rodriguez G, Ramirez R, Falcon O, Leon L, et al. 2006. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int. J. Cancer 119(3):563-70
37. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. 1998. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17:2413-17
38. Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, et al. 2006. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106:87-94
39. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. 2000. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88:814-24
40. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ. 1996. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br. J. Cancer 74:562-67
41. Boyd J, Risinger JI. 1991. Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations. Mol. Carcinog. 4:189-95
42. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. 1994. Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol. Oncol. 53:84-92
43. Leiserowitz GS, Harris SA, Subramaniam M, Keeney GL, Podratz KC, Spelsberg TC. 1993. The proto-oncogene c-fms is overexpressed in endometrial cancer. Gynecol. Oncol. 49:190-96
44. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, et al. 1996. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient. Gynecol. Oncol. 63:238-46
45. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. 1997. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. Eur. J. Cancer 33:1572-77
46. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. 1998. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 58:3526-28
47. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. 1997. p53 gene mutations are common in uterine serous carcinoma and occur as an early event in their pathogenesis. Am. J. Pathol. 150:177-85
48. Sasano H, Comerford J, Wilkinson DS, Schwartz A, Garrett CT. 1990. Serous papillary adenocarcinoma of the endometrium. Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry. Cancer 65:1545-51
49. Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D. 2001. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur. J. Gynaecol. Oncol. 22:122-26
50. Giri PG, Schneider V, Belgrad R. 1981. Clear cell carcinoma of the endometrium: an uncommon entity with a favorable prognosis. Int. J. Radiat. Oncol. Biol. Phys. 7:1383-87
51. Carcangiu ML, Chambers JT. 1995. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Internat. J. Gynecol. Pathol. 14:30-38
52. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. 1998. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum. Pathol. 29:551-58
53. An HJ, Logani S, Isacson C, Ellenson LH. 2004. Molecular characterization of uterine clear cell carcinoma. Mod. Pathol. 17:530-37
54. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. 2000. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356:881-87
55. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. 1994. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:527-37
56. Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J. 2004. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol. Oncol. 92:719-25
57. Prasad M, Wang H, Douglas W, Barakat RR, Ellenson LH. 2005. Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol. Oncol. 96:25-31
58. Mourits MJ, Ten Hoor KA, van der Zee AG, Willemse PH, de Vries EG, Hollema H. 2002. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J. Clin. Pathol. 55:514-19
59. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. 1993. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl. Acad. Sci. USA 90:11162-66
60. Gray CA, Bartol FF, Tarleton BJ, Wiley AA, Johnson GA, et al. 2001. Developmental biology of uterine glands. Biol. Reprod. 65:1311-23
61. Sassoon D. 1999. Wnt genes and endocrine disruption of the female reproductive tract: a genetic approach. Mol. Cellular Endocrinol. 158:1-5
62. Yin Y, Ma L. 2005. Development of the mammalian female reproductive tract. J. Biochem. 137:677-83
63. Miller C, Sassoon DA. 1998. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125:3201-11
64. Mericskay M, Kitajewski J, Sassoon D. 2004. Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development 131:2061-72
65. Ferenczy A, Bergeron C. 1991. Histology of the human endometrium: from birth to senescence. Ann. NY Acad. Sci. 622:6-27
66. Kaaks R, Lukanova A, Kurzer MS. 2002. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 11:1531-43
67. Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, et al. 1997. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc. Natl. Acad. Sci. USA 94:6535-40
68. Bigsby RM, Caperell-Grant A, Berry N, Nephew K, Lubahn D. 2004. Estrogen induces a systemic growth factor through an estrogen receptor-alpha-dependent mechanism. Biol. Reprod. 70:178-83
69. Kurita T, Young P, Brody JR, Lydon JP, O'Malley BW, Cunha GR. 1998. Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology 139:4708-13
70. Buchanan DL, Setiawan T, Lubahn DB, Taylor JA, Kurita T, et al. 1999. Tissue compartment-specific estrogen receptor-α participation in the mouse uterine epithelial secretory response. Endocrinology 140:484-91
71. Kurita T, Medina R, Schabel AB, Young P, Gama P, et al. 2005. The activation function-1 domain of estrogen receptor α in uterine stromal cells is required for mouse but not human uterine epithelial response to estrogen. Differentiation 73:313-22
72. Bjornstrom L, Sjoberg M. 2005. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19:833-42
73. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, et al. 1999. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96:1563-68
74. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. 2000. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 60:3605-11
75. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. 2001. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27:222-24
76. Wang H, Douglas W, Lia M, Edelmann W, Kucherlapati R, et al. 2002. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am. J. Pathol. 160:1481-86
77. Vilgelm A, Lian Z, Wang H, Beauparlant SL, Klein-Szanto A, et al. 2006. Akt-mediated phosphorylation and activation of ERα is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res. 66:3375-80
78. Normanno N, Bianco C, De Luca A, Salomon DS. 2001. The role of EGF-related peptides in tumor growth. Front Biosci. 6:D685-707
79. Marmor MD, Skaria KB, Yarden Y. 2004. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58:903-13
80. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, et al. 2006. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16
81. Falck L, Forsberg JG. 1996. Immunohistochemical studies on the expression and estrogen dependency of EGF and its receptor and C-fos proto-oncogene in the uterus and vagina of normal and neonatally estrogen-treated mice. Anat. Rec. 245:459-71
82. Nelson KG, Takahashi T, Lee DC, Luetteke NC, Bossert NL, et al. 1992. Transforming growth factor-alpha is a potential mediator of estrogen action in the mouse uterus. Endocrinology 131:1657-64
83. Gardner RM, Verner G, Kirkland JL, Stancel GM. 1989. Regulation of uterine epidermal growth factor (EGF) receptors by estrogen in the mature rat and during the estrous cycle. J. Steroid Biochem. 32:339-43
84. Markogiannakis E, Georgoulias V, Margioris AN, Zoumakis E, Stournaras C, Gravanis A. 1997. Estrogens and glucocorticoids induce the expression of c-erbB2/NEU receptor in Ishikawa human endometrial cells. Life Sci. 61:1083-95
85. Nelson KG, Takahashi T, Bossert NL, Walmer DK, McLachlan JA. 1991. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc. Natl. Acad. Sci. USA 88:21-25
86. Tomooka Y, DiAugustine RP, McLachlan JA. 1986. Proliferation of mouse uterine epithelial cells in vitro. Endocrinology 118:1011-18
87. Jaber L, Kan FW. 1998. Non-identical distribution pattern of epidermal growth factor and platelet-derived growth factor in the mouse uterus during the oestrous cycle and early pregnancy. Histochem. J. 30:711-22
88. Slowey MJ, Verhage HG, Fazleabas AT. 1994. Epidermal growth factor, transforming growth factor-alpha, and epidermal growth factor receptor localization in the baboon (Papio anubis) uterus during the menstrual cycle and early pregnancy. J. Soc. Gynecol. Investig. 1:277-84
89. Ohtani S, Okuda K, Ohtani M, Yamada J. 1996. Immunohistochemically- determined changes in the distribution of insulin-like growth factor-I (IGF-I) and epidermal growth factor (EGF) in the bovine endometrium during the estrous cycle. J. Vet. Med. Sci. 58:1211-17
90. Ejskjaer K, Sorensen BS, Poulsen SS, Mogensen O, Forman A, Nexo E. 2005. Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. Mol. Hum. Reprod. 11:543-51
91. Hofmann GE, Scott RTJ, Bergh PA, Deligdisch L. 1991. Immunohistochemical localization of epidermal growth factor in human endometrium, decidua, and placenta. J. Clin. Endocrinol. Metab. 73:882-87
92. Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL, Min KW. 1994. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 73:370-76
93. Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF. 1995. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res. 55:5693-98
94. Srinivasan R, Benton E, McCormick F, Thomas H, Gullick WJ. 1999. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 α, neuregulin-1 β, and betacellulin, in normal endometrium and endometrial cancer. Clin. Cancer Res. 5:2877-83
95. Niikura H, Sasano H, Kaga K, Sato S, Yajima A. 1996. Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. Hum. Pathol. 27:282-89
96. Reynolds RK, Hu C, Baker VV. 1998. Transforming growth factor-α and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines. Gynecol. Oncol. 70:202-9
97. Reinartz JJ, George E, Lindgren BR, Niehans GA. 1994. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum. Pathol. 25:1075-83
98. Wang HS, Chard T. 1999. IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. J. Endocrinol. 161:1-13
99. Murphy LJ, Murphy LC, Friesen HG. 1987. Estrogen induces insulin-like growth factor-I expression in the rat uterus. Mol. Endocrinol. 1:445-50
100. Adesanya OO, Zhou J, Samathanam C, Powell-Braxton L, Bondy CA. 1999. Insulin-like growth factor 1 is required for G2 progression in the estradiol-induced mitotic cycle. Proc. Natl. Acad. Sci. USA 96:3287-91
101. Klotz DM, Hewitt SC, Korach KS, Diaugustine RP. 2000. Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-α. Endocrinology 141:3430-39
102. Baker J, Hardy MP, Zhou J, Bondy C, Lupu F, et al. 1996. Effects of an Igf1 gene null mutation on mouse reproduction. Mol. Endocrinol. 10:903-18
103. Rajkumar K, Dheen T, Krsek M, Murphy LJ. 1996. Impaired estrogen action in the uterus of insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 137:1258-64
104. Zhou J, Dsupin BA, Giudice LC, Bondy CA. 1994. Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. J. Clin. Endocrinol. Metab. 79:1723-34
105. Pearl ML, Talavera F, Gretz IIIHF, Roberts JA, Menon KMJ. 1993. Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC-1-A and KLE. Gynecol. Oncol. 49:325-32
106. Stella MC, Comoglio PM. 1999. HGF: a multifunctional growth factor controlling cell scattering. Int. J. Biochem. Cell Biol. 31:1357-62
107. Moghul A, Lin L, Beedle A, Kanbour-Shakir A, DeFrances MC, et al. 1994. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. Oncogene 9:2045-52
108. Sugawara J, Fukaya T, Murakami T, Yoshida H, Yajima A. 1997. Hepatocyte growth factor stimulated proliferation, migration, and lumen formation of human endometrial epithelial cells in vitro. Biol. Reprod. 57:936-42
109. Yoshida S, Harada T, Iwabe T, Taniguchi F, Fujii A, et al. 2002. Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer. J. Clin. Endocrinol. Metab. 87:2376-83
110. Rider V, Carlone DL, Foster RT. 1997. Oestrogen and progesterone control basic fibroblast growth factor mRNA in the rat uterus. J. Endocrinol. 154:75-84
111. Wei P, Chen XL, Song XX, Han CS, Liu YX. 2004. VEGF, bFGF, and their receptors in the endometrium of rhesus monkey during menstrual cycle and early pregnancy. Mol. Reprod. Dev. 68:456-62
112. Wagatsuma S, Konno R, Sato S, Yajima A. 1998. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 82:520-30
113. Fujimoto J, Hori M, Ichigo S, Tamaya T. 1996. Expressions of the fibroblast growth factor family (FGF-1, -2 and -4) mRNA in endometrial cancers. Tumour Biol. 17:226-33
114. Fujimoto J, Hori M, Ichigo S, Tamaya T. 1995. Expression of basic fibroblast growth factor and its mRNA in uterine endometrial cancers. Invasion Metastasis 15:203-10
115. Logan CY, Nusse R. 2004. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20:781-810
116. Bui TD, Zhang L, Rees MC, Bicknell R, Harris AL. 1997. Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. Br. J. Cancer 75:1131-36
117. Tulac S, Nayak NR, Kao LC, van Waes M, Huang J, et al. 2003. Identification, characterization, and regulation of the canonical Wnt signaling pathway in human endometrium. J. Clin. Endocrinol. Metab. 88:3860-66
118. Miller C, Pavlova A, Sassoon DA. 1998. Differential expression patterns of Wnt genes in the murine female reproductive tract during development and the estrous cycle. Mech. Dev. 76:91-99
119. Hou X, Tan Y, Li M, Dey SK, Das SK. 2004. Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol. Endocrinol. 18:3035-49
120. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. 2001. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17:615-75
121. Cully M, You H, Levine AJ, Mak TW. 2006. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6:184-92
122. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. 2005. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 94:29-86
123. Friday BB, Adjei AA. 2005. K-ras as a target for cancer therapy. Biochim. Biophys. Acta 1756:127-44
124. Mammas IN, Zafiropoulos A, Spandidos DA. 2005. Involvement of the ras genes in female genital tract cancer. Int. J. Oncol. 26:1241-55
125. Yang SH, Sharrocks AD, Whitmarsh AJ. 2003. Transcriptional regulation by the MAP kinase signaling cascades. Gene 320:3-21
126. Levin ER. 2005. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 19:1951-59
127. Razandi M, Pedram A, Park ST, Levin ER. 2003. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 278:2701-12
128. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. 2000. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-41
129. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, et al. 2001. PI3-kinase in concert with Src promotes the S-phase entry of estradiol-stimulated MCF-7 cells. EMBO J. 20:6050-59
130. Edwards DP. 2005. Regulation of signal transduction pathways by estrogen and progesterone. Annu. Rev. Physiol. 67:335-76
131. Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, et al. 2002. Requirement of estrogen receptor-α in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J. Biol. Chem. 277:8531-37
132. Smith CL. 1998. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 58:627-32
133. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, et al. 2000. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141:4503-11
134. Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, et al. 2003. Heregulin-β1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 22:2073-87
135. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. 2001. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for antiestrogen resistance. J. Biol. Chem. 276:9817-24
136. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, et al. 2001. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (ERα) via interaction between ERα and PI3K. Cancer Res. 61:5985-91
137. Rizvi AZ, Wong MH. 2005. Epithelial stem cells and their niche: there's no place like home. Stem Cells 23:150-65
138. Miller SJ, Lavker RM, Sun TT. 2005. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim. Biophys. Acta 1756:25-52
139. Padykula HA. 1991. Regeneration in the primate uterus: the role of stem cells. Ann. NY Acad. Sci. 622:47-56
140. Chan RW, Schwab KE, Gargett CE. 2004. Clonogenicity of human endometrial epithelial and stromal cells. Biol. Reprod. 70:1738-50
141. Taylor HS. 2004. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA 292:81-85
142. Sancho E, Batlle E, Clevers H. 2004. Signaling pathways in intestinal development and cancer. Annu. Rev. Cell Dev. Biol. 20:695-723
143. van den Brink GR, Bleuming SA, Hardwick JC, Schepman BL, Offerhaus GJ, et al. 2004. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nat. Genet. 36:277-82
144. Watt FM. 2004. Unexpected Hedgehog-Wnt interactions in epithelial differentiation. Trends Mol. Med. 10:577-80
145. Takamoto N, Zhao B, Tsai SY, DeMayo FJ. 2002. Identification of Indian hedgehog as a progesterone-responsive gene in the murine uterus. Mol. Endocrinol. 16:2338-48
146. Groszer M, Erickson R, Scripture-Adams DD, Dougherty JD, Le Belle J, et al. 2006. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc. Natl. Acad. Sci. USA 103:111-16